Design Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-17.0%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
-$1.36next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| RESTORE-FA 12-Week Dosing Data Update | 31 Dec 2026 |
| DT-168 Phase 2 FECD Biomarker Data Readout | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Investment Securities Quarterly222.8MTarget: Sufficient to fund planned operations into 2029
RESTORE-FA Trial Patient Enrollment and Dosing Duration Quarterly1,600.0%Target: Completion of 12-week dosing cohorts
Watch Items
- DT-216P2 12-Week Dosing Data in Friedreich's AtaxiaTrigger: Endogenous frataxin (FXN) mRNA and protein levels following 12 weeks of dosingAction: Evaluate registrational development path and initiate regulatory discussions for potential accelerated approval pathways
- DT-168 Phase 2 Biomarker Trial in Fuchs Endothelial Corneal Dystrophy (FECD)Trigger: Safety, tolerability, and corneal endothelium biomarker data readout in 2H 2026Action: Assess clinical proof-of-concept and determine advancement to registrational or late-stage trials
- DT-818 Phase 1 Multiple Ascending Dose (MAD) Trial in Myotonic Dystrophy Type-1 (DM1)Trigger: Initial safety and splicing correction data readout expected in 2027Action: Verify allele-selective transcription reduction of mutant DMPK and plan Phase 2 clinical development
Research as of 19 Jun 2026